An Emerging Pipeline
of Inhibitory Antibodies

Leveraging our deep understanding of enzyme biology and our proprietary antibody discovery and development platform, we are advancing multiple inhibitory antibody candidates into preclinical studies.

amagma-pipeline

While still undisclosed, we are pursuing enzyme targets with strong genetic and/or biologic rationales in disease categories with high unmet medical needs and large patient populations.

amagma-pipeline